Advertisements


Flexion Therapeutics: Reversal In Sentiment?

Flexion Therapeutics: Reversal In Sentiment?.....»»

Category: topSource: seekingalphaNov 9th, 2018

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019.....»»

Category: topSource: seekingalphaJan 8th, 2019

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaJan 4th, 2019

First Week of August 16th Options Trading For Flexion Therapeutics (FLXN)

Stock Options Channel.....»»

Category: topSource: redinewsJan 4th, 2019

Flexion Therapeutics" stock tumbles 11% premarket after weak revenue outlook late Thursday

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchJan 4th, 2019

Flexion shares plummet after weak revenue guidance

Flexion Therapeutics Inc. shares dove 12% in the extended session Thursday after it released preliminary fourth-quarter revenue and guidance for 2019. The company said it expects fourth-quarter revenue of $9.5 million and full-year revenue o.....»»

Category: topSource: marketwatchJan 3rd, 2019

Raymond James: Flexion Therapeutics Estimates Are A Stretch

Flexion Therapeutics Inc (NASDAQ: FLXN) is scheduled.....»»

Category: blogSource: benzingaJan 3rd, 2019

Oversold Conditions For Flexion Therapeutics (FLXN)

Dividend Channel.....»»

Category: topSource: redinewsDec 21st, 2018

Flexion Therapeutics Stock Sees Short Interest Decline 11%

Market News Video.....»»

Category: topSource: redinewsNov 12th, 2018

Flexion Therapeutics" (FLXN) CEO Michael Clayman on Q3 2018 Results - Earnings Call Transcript

Flexion Therapeutics" (FLXN) CEO Michael Clayman on Q3 2018 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaNov 7th, 2018

Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates

Flexion Therapeutics (F.....»»

Category: personnelSource: nytNov 7th, 2018

Commit To Buy Flexion Therapeutics At $12.50, Earn 8.1% Annualized Using Options

Stock Options Channel.....»»

Category: topSource: redinewsSep 24th, 2018

Nomura: Here Are The 3 Signs Stocks Are Becoming Concerned About Excessive Fed Tightening

By Charlie McElligott, head of cross-asset strategy at Nomura Momentum Parties While Softer US Dollar, PBOC Actions Boost Risk-Assets Global risk-sentiment in one asset: Offshore Yuan sees a powerful reversal STRONGER agai.....»»

Category: blogSource: zerohedgeAug 24th, 2018

What Nvidia’s graphics breakthrough means for the company’s stock

Sentiment is bullish on Nvidia’s stock, but any signs of slowing growth could lead to a big reversal......»»

Category: topSource: marketwatchAug 14th, 2018

Flexion Therapeutics (FLXN) Reports Q2 Loss, Lags Revenue Estimates

Flexion Therapeutics (FLXN) d.....»»

Category: worldSource: nytAug 7th, 2018

Take Advantage Of Poor Market Sentiment And Buy Esperion Therapeutics

Take Advantage Of Poor Market Sentiment And Buy Esperion Therapeutics.....»»

Category: topSource: seekingalphaJul 17th, 2018

Flexion Therapeutics Shares Cross Below 200 DMA

Market News Video.....»»

Category: topSource: redinewsJul 2nd, 2018

Flexion Therapeutics started at buy with $39 stock price target at Benchmark

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchJun 28th, 2018

Biotech Analysis Central Pharma News: Puma"s Reversal Win, Pain Therapeutics Suffers Major Blow, Achaogen"s FDA Score

Biotech Analysis Central Pharma News: Puma"s Reversal Win, Pain Therapeutics Suffers Major Blow, Achaogen"s FDA Score.....»»

Category: topSource: seekingalphaJun 27th, 2018

Flexion seen benefiting from Anika Therapeutics" failed Cingal study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 20th, 2018

Flexion to benefit from Anika Therapeutics failed Cingal study, says Wells Fargo

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 19th, 2018